Inhibrx Biosciences, Inc. (INBX)

In the past six months, Inhibrx Biosciences' stock has experienced significant positive movement, rising by 383.46%. As of October 13, 2025, the share price was $34.38, an increase of 121.81% from October 14, 2024, and reached an all-time high of $60.20 on October 24, 2025. Positive topline results for Ozekibart (INBRX-109) led to a surge in the stock price, with shares soaring approximately 70-75% in after-hours trading on October 23rd and continuing to climb over 60% in pre-market hours on October 24, 2025. Following the positive trial results, Inhibrx plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 for ozekibart. On August 13, 2025, the company reported earnings of ($1.85) per share for the quarter, surpassing the consensus estimate of ($2.92) by $1.07, with revenue of $1.30 million for the quarter.

The demand for Inhibrx Biosciences' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by unmet medical needs, the progression of diseases, and the success of clinical trials and regulatory approvals, rather than seasonal patterns. The company's revenue generation currently comes from licensing agreements, collaborations, and milestone payments from partners.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics for life-threatening conditions, particularly in oncology and orphan diseases. The company utilizes proprietary modular protein engineering platforms, including a single-domain antibody (sdAb) platform, to design and develop therapeutic candidates. Its clinical pipeline includes INBRX-109 (Ozekibart), a tetravalent therapeutic candidate targeting death-receptor 5 (DR5) for treating unresectable or metastatic conventional chondrosarcoma and other solid tumors, and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for treating metastatic solid tumors.

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. Its primary operational and developmental activities appear to be based in the U.S.

In the past year, Inhibrx Biosciences' brand reputation has been significantly bolstered by positive clinical trial results, particularly the announcement of overwhelmingly positive topline results from the registrational trial of ozekibart (INBRX-109) for chondrosarcoma on October 23, 2025. This positions ozekibart as a potential first-in-class targeted therapy for a rare and aggressive bone cancer, generating increased investor confidence and validating Inhibrx's platform and pipeline. Despite the positive news, some analysts have maintained a "Reduce" or "Sell" rating on the stock, suggesting caution due to market size concerns and other potential overhangs.

Inhibrx Biosciences, Inc. has significant institutional ownership, with 198 institutional owners and shareholders holding a total of 11,206,869 shares. Major institutional owners include Viking Global Investors Lp, Sanofi, and Perceptive Advisors Llc. Insider ownership is approximately 19% of the company, valued at about US$75 million. While insiders have bought shares in the past year, there have also been insider sales, with $11,287,500.00 in company stock sold in the past three months.